Jiho Choi, MD
Geriatric Medicine · Annandale, VANPI 1225149859
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 267 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by IBSA Pharma Inc. at 24.8% of the total. Reporting peaked in 2019 at $1,011 and has fallen 58.1% since, to $424 in 2025. Among geriatric medicine clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 267 payments — averaging $19.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- IBSA Pharma Inc.$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$549
- Novo Nordisk$386
- Amarin Pharma, Inc.$369
- Johnson & Johnson$306
- Scilex Pharmaceuticals Inc.$295
- plus $2K from 19 others
What the payments were for
- Food & beverage$5,03499%
- Education$711%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| IBSA Pharma Inc. | 63 | $1,268 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 39 | $549 |
| Novo Nordisk | 29 | $386 |
| Amarin Pharma, Inc. | 14 | $369 |
| Johnson & Johnson | 10 | $306 |
| Scilex Pharmaceuticals Inc. | 17 | $295 |
| Amgen(2 entities) | 3 | $270 |
| Sumitomo Pharma America, Inc. | 11 | $265 |
| Sunovion Pharmaceuticals Inc. | 13 | $197 |
| Lilly USA, LLC | 9 | $179 |
| Astellas Pharma US Inc | 7 | $178 |
| AbbVie | 9 | $164 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $143 |
| Aimmune Therapeutics, Inc. | 5 | $108 |
| Nestle Healthcare Nutrition Inc. | 4 | $78 |
| Boehringer Ingelheim | 4 | $71 |
| Hikma Pharmaceuticals USA | 4 | $62 |
| Eyevance Pharmaceuticals LLC | 4 | $62 |
| Radius Health, Inc. | 2 | $34 |
| Kowa Pharmaceuticals America, Inc. | 2 | $26 |
| Vivus LLC | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Bayer | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Evoke Pharma, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,105 in reported general payments places this provider in the 95th percentile of 90 geriatric medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Sodium | 749 | $472,448 |
| LicartDiclofenac Epolamine | 425 | $312,011 |
| Lidocaine | 1,003 | $209,339 |
| Diclofenac Epolamine | 254 | $169,830 |
| VascepaIcosapent Ethyl | 179 | $143,339 |
| ZtlidoLidocaine | 189 | $137,561 |
| LinzessLinaclotide | 90 | $117,411 |
| RestasisCyclosporine | 64 | $101,927 |
| OzempicSemaglutide | 59 | $86,610 |
| TradjentaLinagliptin | 49 | $59,758 |
| ProliaDenosumab | 31 | $54,385 |
| ZenpepLipase/Protease/Amylase | 23 | $49,916 |
| Ibuprofen-FamotidineIbuprofen/Famotidine | 85 | $42,686 |
| JanuviaSitagliptin Phosphate | 44 | $40,641 |
| JardianceEmpagliflozin | 31 | $37,051 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| IBSA Pharma Inc.Licart | $1,268 | $312,011425 claims |
| AbbVieLinzess, Restasis, Creon | $164 | $239,258167 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $295 | $137,561189 claims |
| Boehringer IngelheimTradjenta, Jardiance, Spiriva Respimat | $71 | $108,71795 claims |
| Novo NordiskOzempic | $386 | $86,61059 claims |
| AmgenProlia | $270 | $54,38531 claims |
| Aimmune Therapeutics, Inc.Zenpep | $108 | $49,91623 claims |
| Astellas Pharma US IncMyrbetriq | $178 | $30,80928 claims |
| Johnson & JohnsonXarelto | $306 | $29,38128 claims |
| Lilly USA, LLCMounjaro | $179 | $22,83720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 90 geriatric medicine providers in Virginia.
Other geriatric medicine in Annandale
- Stefan GravensteinNorfolk$306K
- Cara RavagliRoanoke$103K
- Jennifer JonkersAbingdon$8K
- Vijay ChadhaReston$7K
- Christopher WebbLynchburg$3K
- Alexandra MullinHenrico$1K
- Sarita SubramaniamWilliamsburg$1K
- Kevin MurrayNorfolk$958
- Tabassum SubuhiRoanoke$733
- Anuradha ReddyFairfax$492
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.